Biogen will report 96-week extension results from the Phase 2 CELIA trial of diranersen, an antisense oligonucleotide designed to reduce production of tau protein by targeting MAPT mRNA, alongside 76-week tau biomarker and amyloid PET data in 416 participants with mild cognitive impairment or mild Alzheimer's dementia. The company will also present initial five-year open-label extension findings for lecanemab from Clarity AD, three-year real-world data, and analyses of maintenance dosing, subcutaneous administration, and ARIA safety. Together the datasets test whether sustained protein-clearance strategies hold durable effects over multi-year horizons.
Key Points
- Diranersen targets MAPT mRNA to lower tau production directly
- Lecanemab five-year extension and three-year real-world data reported
- Maintenance dosing, subcutaneous delivery, and ARIA safety analyzed
Longevity Analysis
Cognitive decline tracks the accumulation of misfolded proteins the brain can no longer clear, making duration of treatment effect — not short-term biomarker movement — the decisive question for anyone planning decades of cognitive capacity. Five-year extension data and real-world evidence address whether benefit compounds or plateaus once clearance mechanisms are pharmacologically supported, while ARIA analyses define the cost side of immune-mediated amyloid removal. Amyloid PET and tau biomarker readouts also sharpen the ability to identify who is accumulating pathology years before symptoms surface, shifting intervention upstream where the regenerative capacity of neural tissue remains intact.
Original published by LT Wire.